Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fosaprepitant
Drug ID BADD_D00962
Description Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
Indications and Usage For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
Marketing Status approved
ATC Code Not Available
DrugBank ID DB06717
KEGG ID D10895
MeSH ID C579707
PubChem ID 135413538
TTD Drug ID Not Available
NDC Product Code 43598-948; 72205-054; 72205-083; 16714-929; 68180-690; 43598-859; 71839-104; 63323-972; 70710-1615; 16729-240; 68001-517; 0781-3497; 68001-421; 16714-120; 69539-181; 72205-026; 60505-6105; 69097-830; 69539-034; 67457-889; 0591-4385
UNII 6L8OF9XRDC
Synonyms fosaprepitant | Emend for injection | fosaprepitant dimeglumine | L 785,298 | L785,298 | L-785,298
Chemical Information
Molecular Formula C23H22F7N4O6P
CAS Registry Number 172673-20-0
SMILES CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC2C(N(CCO2)CC3=NN(C(=O)N3)P(=O)(O)O)C4=CC=C( C=C4)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Urticaria23.04.02.001; 10.01.06.001--
Visual acuity reduced06.02.10.012; 17.17.01.011--
Weight decreased13.15.01.005--
Wheezing22.03.01.009--
Infusion site erythema12.07.05.009; 08.02.05.008; 23.03.06.016--Not Available
Subileus07.13.01.004--Not Available
Lymphatic disorder01.09.01.003--Not Available
Infusion site induration12.07.05.010; 08.02.05.009--Not Available
Infusion site pain12.07.05.002; 08.02.05.014--Not Available
Infusion site pruritus23.03.12.006; 12.07.05.005; 08.02.05.004--Not Available
Cognitive disorder19.21.02.001; 17.03.03.003--
Staphylococcal infection11.02.05.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Blood disorder01.05.01.004--Not Available
Neutropenic colitis07.08.01.014; 01.02.03.010--Not Available
Infusion site thrombosis24.01.01.022; 12.07.05.007; 08.02.05.006--Not Available
Procedural nausea12.02.03.003; 07.01.07.005--Not Available
Gastrointestinal sounds abnormal07.01.01.002--Not Available
The 4th Page    First    Pre   4 5    Next   Last    Total 5 Pages